Newborn Phosphocalcic Metabolism After Intravenous Iron Administration During Pregnancy
NCT ID: NCT06108258
Last Updated: 2023-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
43 participants
OBSERVATIONAL
2022-09-23
2023-03-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators conducted a prospective, single-center, observational study in the Geneva University Hospitals (HUG), from September 2022 to March 2023. Pregnant women treated either with IV iron or with oral iron during pregnancy were included. At delivery, a maternal blood sample to assess hemoglobin, hematocrit, ferritin, phosphate and calcium and an umbilical cord blood sample to assess levels of phosphate and calcium were collected. Difference in demographics and clinical characteristics between the two groups were explored using univariate analyses. Multivariate analyses were performed to test the contribution of IV iron substitution on cord blood phosphatemia and calcemia, considering potential confounding factors. Neonatal HP was defined as a phosphate level lower than 1.3 mmol/L.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial
NCT03438227
Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy
NCT05462704
Serum Hepcidin in Pregnant Women and the Association With Pregnancy Outcome
NCT03792464
Pregnancy Outcome in Women With an Iron Deficiency in the First Trimester
NCT05262634
Iron Metabolism Parameters At First Trimester and preGnancy outcomE
NCT03176147
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral iron
No interventions assigned to this group
IV iron
IV iron administration
IV iron administration during pregnancy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IV iron administration
IV iron administration during pregnancy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Term (\>37SA) pregnancy
* Oral or IV iron substitution from second trimester
Exclusion Criteria
* Fetal anomalies
* Preterm birth
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Geneva
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fanny Schumacher
resident doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Geneva University Hospitals
Geneva, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-00197
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.